Is metabolic stress a common denominator in inflammatory bowel disease?

Inflammatory Bowel Diseases

Volumn 17, Issue 9, 2011, Pages 2008-2018

  Schoultz, Ida ^a   Söderholm, Johan D ^b   McKay, Derek M ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

commensal microflora; inflammatory bowel disease; metabolic stress

Indexed keywords

2,4 DINITROPHENOL; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANTIOXIDANT; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CELECOXIB; DEFENSIN; ENEMA; FRUCTOSE OLIGOSACCHARIDE; GAMMA INTERFERON; HYDROCHLORIC ACID; HYDROGEN PEROXIDE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INTERLEUKIN 10; INULIN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXYNITRITE; PREBIOTIC AGENT; REACTIVE OXYGEN METABOLITE; RETINOIC ACID INDUCIBLE PROTEIN I; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA;

ANAEROBIC GLYCOLYSIS; AUTOPHAGY; CAMPYLOBACTER JEJUNI; CELL FUNCTION; CELL MEMBRANE PERMEABILITY; CELL STRESS; CELL SURFACE; CITROBACTER RODENTIUM; CLOSTRIDIUM DIFFICILE; COLITIS; COLON ISCHEMIA; COMMENSALISM; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ENDOCYTOSIS; ENERGY YIELD; ENTERITIS; ENTEROPATHY; EPITHELIAL BARRIER FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GLUCOSE METABOLISM; HELICOBACTER PYLORI; HUMAN; INTESTINE CELL; INTESTINE EPITHELIUM CELL; INTESTINE MUCOSA PERMEABILITY; MENTAL STRESS; METABOLIC STRESS; MITOCHONDRION; MUCUS SECRETION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; ROTAVIRUS; SALMONELLA TYPHIMURIUM; SHIGELLA FLEXNERI; SIGNAL TRANSDUCTION; STOMACH PH; STOMACH ULCER; TIGHT JUNCTION; TRANSMISSION ELECTRON MICROSCOPY; YERSINIA ENTEROCOLITICA;

HUMANS; INFLAMMATORY BOWEL DISEASES; METAGENOME; PROGNOSIS; STRESS, PHYSIOLOGICAL;

EID: 80051512499     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21556     Document Type: Review

References (112)

1. Hamady M, Knight R., Microbial community profiling for human microbiome projects: tools, techniques, and challenges. Genome Res. 2009; 19: 1141-1152.
2. Chung H, Kasper DL., Microbiota-stimulated immune mechanisms to maintain gut homeostasis. Curr Opin Immunol. 2010; 22: 455-460.
3. Roediger WE., The colonic epithelium in ulcerative colitis: an energy-deficiency disease ? Lancet. 1980; 2: 712-715. (Pubitemid 10060060)
4. Rosenstiel P, Sina C, Franke A, et al. Towards a molecular risk map-recent advances on the etiology of inflammatory bowel disease. Semin Immunol. 2009; 21: 334-345.
5. Melmed GY, Targan SR., Future biologic targets for IBD:, potentials and pitfalls. Nat Rev Gastroenterol Hepatol. 2010; 7: 110-117.
6. Molodecky NA, Kaplan GG., Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol. 2010; 6: 339-346.
7. Benko S, Philpott DJ, Girardin SE., The microbial and danger signals that activate Nod-like receptors. Cytokine. 2008; 43: 368-373.
8. Marchiando AM, Graham WV, Turner JR., Epithelial barriers in homeostasis and disease. Annu Rev Pathol. 2010; 5: 119-144.
9. Beaurepaire C, Smyth D, McKay DM., Interferon-Î3 regulation of intestinal epithelial permeability. J Interferon Cytokine Res. 2009; 29: 133-144.
10. Gitter AH, Bendfeldt K, Schulzke JD, et al. Leaks in the epithelial barrier caused by spontaneous and TNF-α-induced single-cell apoptosis. FASEB J. 2000; 14: 1749-1753.
11. Wang F, Graham WV, Wang Y, et al. Interferon-Î3 and tumor necrosis factor-α synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol. 2005; 166: 409-419. (Pubitemid 40189038)
12. Zeissig S, Burgel N, Gunzel D, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut. 2007; 56: 61-72. (Pubitemid 46044890)
13. Keita AV, Salim SY, Jiang T, et al. Increased uptake of non-pathogenic E. coli via the follicle-associated epithelium in longstanding ileal Crohn's disease. J Pathol. 2008; 215: 135-144. (Pubitemid 351786032)
14. Nazli A, Yang PC, Jury J, et al. Epithelia under metabolic stress perceive commensal bacteria as a threat. Am J Pathol. 2004; 164: 947-957. (Pubitemid 38235476)
15. Soderholm JD, Olaison G, Lindberg E, et al. Different intestinal permeability patterns in relatives and spouses of patients with Crohn's disease: an inherited defect in mucosal defence ? Gut. 1999; 44: 96-100. (Pubitemid 29143287)
16. Soderholm JD, Peterson KH, Olaison G, et al. Epithelial permeability to proteins in the noninflamed ileum of Crohn's disease ? Gastroenterology. 1999; 117: 65-72. (Pubitemid 29297621)
17. McKay DM, Watson JL, Wang A, et al. Phosphatidylinositol 3'-kinase is a critical mediator of interferon-Î3-induced increases in enteric epithelial permeability. J Pharmacol Exp Ther. 2007; 320: 1013-1022. (Pubitemid 46294056)
18. Soderholm JD, Streutker C, Yang PC, et al. Increased epithelial uptake of protein antigens in the ileum of Crohn's disease mediated by tumour necrosis factor-α. Gut. 2004; 53: 1817-1824. (Pubitemid 39556903)
19. Clark E, Hoare C, Tanianis-Hughes J, et al. Interferon-Î3 induces translocation of commensal Escherichia coli across gut epithelial cells via a lipid raft-mediated process. Gastroenterology. 2005; 128: 1258-1267. (Pubitemid 40712177)
20. Schurmann G, Bruwer M, Klotz A, et al. Transepithelial transport processes at the intestinal mucosa in inflammatory bowel disease. Int J Colorectal Dis. 1999; 14: 41-46. (Pubitemid 29295302)
21. McGuckin MA, Eri R, Simms LA, et al. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis. 2009; 15: 100-113.
22. Salim SY, Soderholm JD., Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis. 2010; [Epub ahead of print].
23. Kaser A, Zeissig S, Blumberg RS., Inflammatory bowel disease. Annu Rev Immunol. 2010; 28: 573-621.
24. Arrieta MC, Madsen K, Doyle J, et al. Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse. Gut. 2009; 58: 41-48.
25. Olson TS, Reuter BK, Scott KG, et al. The primary defect in experimental ileitis originates from a nonhematopoietic source. J Exp Med. 2006; 203: 541-552.
26. Resta-Lenert S, Smitham J, Barrett KE., Epithelial dysfunction associated with the development of colitis in conventionally housed mdr1a-/- mice. Am J Physiol Gastrointest Liver Physiol. 2005; 289: G153-162. (Pubitemid 40944234)
27. Kanwar JR, Kanwar RK, Burrow H, et al. Recent advances on the roles of NO in cancer and chronic inflammatory disorders. Curr Med Chem. 2009; 16: 2373-2394.
28. Oz HS, Chen TS, McClain CJ, et al. Antioxidants as novel therapy in a murine model of colitis. J Nutr Biochem. 2005; 16: 297-304. (Pubitemid 41556919)
29. Szanto I, Rubbia-Brandt L, Kiss P, et al. Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel disease. J Pathol. 2005; 207: 164-176. (Pubitemid 41404147)
30. McGuckin MA, Eri RD, Das I, et al. ER stress and the unfolded protein response in intestinal inflammation. Am J Physiol Gastrointest Liver Physiol. 2010; 298: G820-832.
31. Soderholm JD, Olaison G, Peterson KH, et al. Augmented increase in tight junction permeability by luminal stimuli in the non-inflamed ileum of Crohn's disease. Gut. 2002; 50: 307-313. (Pubitemid 34161043)
32. Hsieh SY, Shih TC, Yeh CY, et al. Comparative proteomic studies on the pathogenesis of human ulcerative colitis. Proteomics. 2006; 6: 5322-5331.
33. Nell S, Suerbaum S, Josenhans C., The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models. Nat Rev Microbiol. 2010; 8: 564-577.
34. Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007; 104: 13780-13785. (Pubitemid 350003397)
35. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2006; 55: 205-211. (Pubitemid 43117279)
36. Sokol H, Seksik P, Furet JP, et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis. 2009; 15: 1183-1189.
37. Barcenilla A, Pryde SE, Martin JC, et al. Phylogenetic relationships of butyrate-producing bacteria from the human gut. Appl Environ Microbiol. 2000; 66: 1654-1661. (Pubitemid 30185646)
38. Segain JP, Raingeard de la Bletiere D, Bourreille A, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut. 2000; 47: 397-403.
39. Hansen R, Thomson JM, El-Omar EM, et al. The role of infection in the aetiology of inflammatory bowel disease. J Gastroenterol. 2010; 45: 266-276.
40. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002; 122: 44-54. (Pubitemid 34049193)
41. Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology. 2004; 127: 412-421. (Pubitemid 39091889)
42. He D, Sougioultzis S, Hagen S, et al. Clostridium difficile toxin A triggers human colonocyte IL-8 release via mitochondrial oxygen radical generation. Gastroenterology. 2002; 122: 1048-1057. (Pubitemid 34267287)
43. Jesenberger V, Procyk KJ, Yuan J, et al. Salmonella-induced caspase-2 activation in macrophages: a novel mechanism in pathogen-mediated apoptosis. J Exp Med. 2000; 192: 1035-1046.
44. Maki M, Vesikari T, Rantala I, et al. Yersiniosis in children. Arch Dis Child. 1980; 55: 861-865. (Pubitemid 11209427)
45. Ma C, Wickham ME, Guttman JA, et al. Citrobacter rodentium infection causes both mitochondrial dysfunction and intestinal epithelial barrier disruption in vivo: role of mitochondrial associated protein (Map). Cell Microbiol. 2006; 8: 1669-1686. (Pubitemid 44350025)
46. Dickman KG, Hempson SJ, Anderson J, et al. Rotavirus alters paracellular permeability and energy metabolism in Caco-2 cells. Am J Physiol Gastrointest Liver Physiol. 2000; 279: G757-766.
47. Carneiro LA, Travassos LH, Soares F, et al. Shigella induces mitochondrial dysfunction and cell death in nonmyleoid cells. Cell Host Microbe. 2009; 5: 123-136.
48. Zareie M, Riff J, Donato K, et al. Novel effects of the prototype translocating Escherichia coli, strain C25 on intestinal epithelial structure and barrier function. Cell Microbiol. 2005; 7: 1782-1797. (Pubitemid 41685271)
49. Kuwano Y, Tominaga K, Kawahara T, et al. Tumor necrosis factor-α activates transcription of the NADPH oxidase organizer 1 (NOXO1) gene and upregulates superoxide production in colon epithelial cells. Free Radic Biol Med. 2008; 45: 1642-1652.
50. Baregamian N, Song J, Bailey CE, et al. Tumor necrosis factor-α and apoptosis signal-regulating kinase 1 control reactive oxygen species release, mitochondrial autophagy, and c-Jun N-terminal kinase/p38 phosphorylation during necrotizing enterocolitis. Oxid Med Cell Longev. 2009; 2: 297-306.
51. Kamizato M, Nishida K, Masuda K, et al. Interleukin 10 inhibits interferon-Î3- and tumor necrosis factor-α-stimulated activation of NADPH oxidase 1 in human colonic epithelial cells and the mouse colon. J Gastroenterol. 2009; 44: 1172-1184.
52. Ebert EC, Panja A, Das KM, et al. Patients with inflammatory bowel disease may have a transforming growth factor-β-, interleukin (IL)-2- or IL-10-deficient state induced by intrinsic neutralizing antibodies. Clin Exp Immunol. 2009; 155: 65-71.
53. D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998; 114: 262-267. (Pubitemid 28093532)
54. Ramachandran A, Patra S, Balasubramanian KA., Intestinal mitochondrial dysfunction in surgical stress. J Surg Res. 2001; 99: 120-128. (Pubitemid 32613968)
55. Willoughby RP, Harris KA, Carson MW, et al. Intestinal mucosal permeability to 51Cr-ethylenediaminetetraacetic acid is increased after bilateral lower extremity ischemia-reperfusion in the rat. Surgery. 1996; 120: 547-553. (Pubitemid 26337132)
56. Colgan SP, Taylor CT., Hypoxia: an alarm signal during intestinal inflammation. Nat Rev Gastroenterol Hepatol. 2010; 7: 281-287.
57. Brahme F, Lindstrom C., A comparative radiographic and pathological study of intestinal vaso-architecture in Crohn's disease and in ulcerative colitis. Gut. 1970; 11: 928-940.
58. Hatoum OA, Binion DG, Otterson MF, et al. Acquired microvascular dysfunction in inflammatory bowel disease: loss of nitric oxide-mediated vasodilation. Gastroenterology. 2003; 125: 58-69. (Pubitemid 36799107)
59. Yoo BH, Wu X, Derouet M, et al. Hypoxia-induced downregulation of autophagy mediator Beclin 1 reduces the susceptibility of malignant intestinal epithelial cells to hypoxia-dependent apoptosis. Autophagy. 2009; 5: 1166-1179.
60. Scherz-Shouval R, Elazar Z., Regulation of autophagy by ROS:, physiology and pathology. Trends Biochem Sci. 2010; [Epub ahead of print].
61. Higuchi K, Umegaki E, Watanabe T, et al. Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol. 2009; 44: 879-888.
62. Bjarnason I, Takeuchi K., Intestinal permeability in the pathogenesis of NSAID-induced enteropathy. J Gastroenterol. 2009; 44 (suppl 19): 23-29.
63. Montrose DC, Kadaveru K, Ilsley JN, et al. cPLA2 is protective against COX inhibitor-induced intestinal damage. Toxicol Sci. 2010; 117: 122-132.
64. Basivireddy J, Vasudevan A, Jacob M, et al. Indomethacin-induced mitochondrial dysfunction and oxidative stress in villus enterocytes. Biochem Pharmacol. 2002; 64: 339-349. (Pubitemid 34775312)
65. Somasundaram S, Sigthorsson G, Simpson RJ, et al. Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat. Aliment Pharmacol Ther. 2000; 14: 639-650. (Pubitemid 30240758)
66. Gabe SM, Bjarnason I, Tolou-Ghamari Z, et al. The effect of tacrolimus (FK506) on intestinal barrier function and cellular energy production in humans. Gastroenterology. 1998; 115: 67-74. (Pubitemid 28307289)
67. Madsen KL, Yanchar NL, Sigalet DL, et al. FK506 increases permeability in rat intestine by inhibiting mitochondrial function. Gastroenterology. 1995; 109: 107-114.
68. De Jonge HR., Toxicity of tetracyclines in rat-small-intestinal epithelium and liver. Biochem Pharmacol. 1973; 22: 2659-2677.
69. Grace WJ., Life stress and gastro-intestinal diseases. Am Pract Dig Treat. 1953; 4: 848-852.
70. Bernstein CN, Singh S, Graff LA, et al. A prospective population-based study of triggers of symptomatic flares in IBD. Am J Gastroenterol. 2010; 105: 1994-2002.
71. Mawdsley JE, Rampton DS., Psychological stress in IBD:, new insights into pathogenic and therapeutic implications. Gut. 2005; 54: 1481-1491. (Pubitemid 41375207)
72. Goodhand JR, Wahed M, Rampton DS., Management of stress in inflammatory bowel disease: a therapeutic option ? Expert Rev Gastroenterol Hepatol. 2009; 3: 661-679.
73. Soderholm JD, Perdue MH., Stress and gastrointestinal tract. II. Stress and intestinal barrier function. Am J Physiol Gastrointest Liver Physiol. 2001; 280: G7-G13.
74. Barclay GR, Turnberg LA., Effect of cold-induced pain on salt and water transport in the human jejunum. Gastroenterology. 1988; 94: 994-998.
75. Santos J, Saperas E, Nogueiras C, et al. Release of mast cell mediators into the jejunum by cold pain stress in humans. Gastroenterology. 1998; 114: 640-648. (Pubitemid 28160398)
76. Wallon C, Yang PC, Keita AV, et al. Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut. 2008; 57: 50-58.
77. Barreau F, Ferrier L, Fioramonti J, et al. Neonatal maternal deprivation triggers long term alterations in colonic epithelial barrier and mucosal immunity in rats. Gut. 2004; 53: 501-506. (Pubitemid 38372973)
78. Meddings JB, Swain MG., Environmental stress-induced gastrointestinal permeability is mediated by endogenous glucocorticoids in the rat. Gastroenterology. 2000; 119: 1019-1028.
79. Saunders PR, Kosecka U, McKay DM, et al. Acute stressors stimulate ion secretion and increase epithelial permeability in rat intestine. Am J Physiol. 1994; 267: G794-799.
80. Velin AK, Ericson AC, Braaf Y, et al. Increased antigen and bacterial uptake in follicle associated epithelium induced by chronic psychological stress in rats. Gut. 2004; 53: 494-500. (Pubitemid 38372972)
81. Soderholm JD, Yang PC, Ceponis P, et al. Chronic stress induces mast cell-dependent bacterial adherence and initiates mucosal inflammation in rat intestine. Gastroenterology. 2002; 123: 1099-1108.
82. Farhadi A, Keshavarzian A, Van de Kar LD, et al. Heightened responses to stressors in patients with inflammatory bowel disease. Am J Gastroenterol. 2005; 100: 1796-1804. (Pubitemid 41648436)
83. Nisoli E, Clementi E, Paolucci C, et al. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science. 2003; 299: 896-899. (Pubitemid 36182449)
84. Nazli A, Wang A, Steen O, et al. Enterocyte cytoskeleton changes are crucial for enhanced translocation of non-pathogenic Escherichia coli across metabolically stressed gut epithelia. Infect Immun. 2006; 74: 192-201. (Pubitemid 43023074)
85. Lewis K, Lutgendorff F, Phan V, et al. Enhanced translocation of bacteria across metabolically stressed epithelia is reduced by butyrate. Inflamm Bowel Dis. 2010; 16: 1138-1148.
86. Lewis K, Caldwell J, Phan V, et al. Decreased epithelial barrier function evoked by exposure to metabolic stress and non-pathogenic E. coli is enhanced by TNF-α. Am J Physiol Gastrointest Liver Physiol. 2008; 294: G669-678. (Pubitemid 351468760)
87. Lewis K, McKay DM., Metabolic stress evokes decreases in epithelial barrier function. Ann N Y Acad Sci. 2009; 1165: 327-337.
88. Ragnarsson EG, Schoultz I, Gullberg E, et al. Yersinia pseudotuberculosis induces transcytosis of nanoparticles across human intestinal villus epithelium via invasin-dependent macropinocytosis. Lab Invest. 2008; 88: 1215-1226.
89. Scherz-Shouval R, Elazar Z. ROS, mitochondria and the regulation of autophagy. Trends Cell Biol. 2007; 17: 422-427.
90. Mates JM, Segura JA, Alonso FJ, et al. Intracellular redox status and oxidative stress: implications for cell proliferation, apoptosis, and carcinogenesis. Arch Toxicol. 2008; 82: 273-299.
91. Fujita N, Itoh T, Omori H, et al. The Atg16L complex specifies the site of LC3 lipidation for membrane biogenesis in autophagy. Mol Biol Cell. 2008; 19: 2092-2100.
92. Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn's disease in ATG16L1. Nat Genet. 2007; 39: 207-211. (Pubitemid 46184351)
93. Kuballa P, Huett A, Rioux JD, et al. Impaired autophagy of an intracellular pathogen induced by a Crohn's disease associated ATG16L1 variant. PLoS One. 2008; 3: e3391.
94. Cadwell K, Liu JY, Brown SL, et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature. 2008; 456: 259-263.
95. Lapaquette P, Glasser AL, Huett A, et al. Crohn's disease-associated adherent-invasive E. coli are selectively favoured by impaired autophagy to replicate intracellularly. Cell Microbiol. 2010; 12: 99-113.
96. Aprahamian CJ, Lorenz RG, Harmon CM, et al. Toll-like receptor 2 is protective of ischemia-reperfusion-mediated small-bowel injury in a murine model. Pediatr Crit Care Med. 2008; 9: 105-109.
97. Lipinski S, Till A, Sina C, et al. DUOX2-derived reactive oxygen species are effectors of NOD2-mediated antibacterial responses. J Cell Sci. 2009; 122: 3522-3530.
98. Tschopp J, Schroder K., NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production ? Nat Rev Immunol. 2010; 10: 210-215.
99. Villani AC, Lemire M, Fortin G, et al. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet. 2009; 41: 71-76.
100. Schoultz I, Verma D, Halfvarsson J, et al. Combined polymorphisms in genes encoding the inflammasome components NALP3 and CARD8 confer susceptibility to Crohn's disease in Swedish men. Am J Gastroenterol. 2009; 104: 1180-1188.
101. Looijer-van Langen MA, Dieleman LA., Prebiotics in chronic intestinal inflammation. Inflamm Bowel Dis. 2009; 15: 454-462.
102. Assisi RF., Combined butyric acid/mesalazine treatment in ulcerative colitis with mild-moderate activity. Results of a multicentre pilot study. Minerva Gastroenterol Dietol. 2008; 54: 231-238.
103. Roda A, Simoni P, Magliulo M, et al. A new oral formulation for the release of sodium butyrate in the ileo-cecal region and colon. World J Gastroenterol. 2007; 13: 1079-1084. (Pubitemid 46511010)
104. Tedelind S, Westberg F, Kjerrulf M, et al. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol. 2007; 13: 2826-2832. (Pubitemid 47007897)
105. Thibault R, De Coppet P, Daly K, et al. Down-regulation of the monocarboxylate transporter 1 is involved in butyrate deficiency during intestinal inflammation. Gastroenterology. 2007; 133: 1916-1927. (Pubitemid 350180798)
106. Thibault R, Blachier F, Darcy-Vrillon B, et al. Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport deficiency. Inflamm Bowel Dis. 2010; 16: 684-695.
107. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, et al. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat Med. 1996; 2: 998-1004. (Pubitemid 26306838)
108. Karrash T, Jobin C., NF-κB and the intestine: friend or foe ? Inflamm Bowel Dis. 2008; 14: 114-124.
109. Porteous CM, Logan A, Evans C, et al. Rapid uptake of lipophilic triphenylphosphonium cations by mitochondria in vivo following intravenous injection: Implications for mitochondria-specific therapies and probes. Biochim Biophys Acta. 2010; 1800: 1009-1017.
110. Kelso GF, Porteous CM, Coulter CV, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem. 2001; 276: 4588-4596.
111. Smith RA, Murphy MP., Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann N Y Acad Sci. 2010; 1201: 96-103.
112. Schon EA, Dimauro S, Hirano M, et al. Therapeutic prospects for mitochondrial disease. Trends Mol Med. 2010; 16: 268-276.